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Transforming growth factor beta 1 (TGF-f,1) produced in tumour tissue
after chemotherapy acts as a lymphokine-activated killer attractant
Y Kuramitsul, M Nishibel, M Kobayashi', Y Togashil, L Yuan', M Takizawal, F Okada2 and
M Hosokawa'
Laboratories of'Pathology and 2Cell Biology, Cancer Institute, Hokkaido University School ofMedicine, Kita-15, Nishi-7, Kitaku
Sapporo, 060, Japan.
Summary Using an under agarose migration (UAM) assay, we studied lymphokine-activated killer (LAK)-
attractant activity in cultured conditioned medium of tumour tissues after chemotherapy as a possible
mechanism of enhanced LAK cell accumulation into tumour tissues after chemotherapy. BMT-11 is a
fibrosarcoma developed in C57BL/6 mice. The conditioned medium of BMT-11 tumour tissues obtained from
mice treated with various anti-cancer drugs had chemotactic activity for LAK cells (LAK-attractant activity).
mRNA expression of interleukin (IL)-la, IL-6, IL-8, interferon (IFN)-y, and tumour necrosis factor (TNF)-a
was observed in untreated tumour tissues, which were not enhanced by cyclophosphamide treatment. mRNA
expression of TGF-,IB was not detected in untreated tumour tissues by reverse transcription-polymerase chain
reaction (RT-PCR), but was detected in tumour tissues treated with cyclophosphamide. Recombinant human
TGF-,B1 showed LAK-attractant activity at a concentration of 0.1 ng ml- 1 and 1 ng ml-', whereas fresh
splenocytes were not attracted by TGF-f,1. Anti-TGF-,B1 antibody inhibited LAK-attractant activity in the
conditioned medium of tumour tissues treated with cyclophosphamide to approximately 35% that of control at
100 Mg ml-l. These findings indicate that TGF-,13 produced in the tumour tissues of mice treated with anti-
cancer drugs could be a LAK attractant. By a 4 h 51Cr release assay of natural killer cell-resistant BMT- 11
tumour cells, we observed that TGF-,B1 at a concentration from 0.01 ng ml-1 to 10 ng ml-1 did not inhibit
LAK activity in an effector phase. Taken together, we suggest that TGF-,B1 produced in tumour tissues after
chemotherapy participates in gathering transferred LAK cells and contributes to the therapeutic effects of
transferred LAK cells.
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Lymphokine-activated killer (LAK) cells are interleukin (IL)-
2-activated natural killer (NK) or T cells, and show strong
cytotoxic activity against a broad variety of tumour cells,
including NK-resistant tumour cells (Grimm et al., 1982;
Rosenberg et al., 1985). It was much expected that LAK cells
would be a new potent anti-tumour effector in adoptive
immunotherapy; however, adoptive immunotherapy with
LAK cells was found to produce only limited clinical effects
on human cancers, including melanomas and renal cell
carcinomas. One of the reasons for this discrepancy is that
transferred LAK cells are unable to accumulate efficiently at
tumour sites. Many investigators studying LAK cell
distribution in vivo agreed that LAK cells are distributed at
the liver and spleen 24 h after i.v. transfer. However,
accumulation of LAK cells at the tumour site is less than
5% of all transferred cells (Lotze et al., 1980; Hosokawa et
al., 1988; Maghazachi et al., 1988; Ames et al., 1989; Felgar
et al., 1990; Kawata et al., 1990; Futami et al., 1991). The
poor tumour-specific accumulation of LAK cells might be
due to a lack of specific recognition of tumour cells. Some
trials have been performed to give LAK cells specificity for
tumour recognition using bispecific antibody (Nitta et al.,
1990, 1991). We previously reported that cancer chemother-
apy before LAK cell transfer increased effects of LAK
adoptive immunotherapy synergistically, and that transferred
LAK cell accumulation in tumour tissues was enhanced in
mice by treatment with cancer chemotherapeutic agents
(Kawata et al., 1990; Hosokawa et al., 1992). Therefore, we
have attempted to clarify mechanisms responsible for the
enhanced accumulation at the tumour tissues of LAK cells
transferred after chemotherapy from the viewpoint of
chemotaxis for LAK cells.
Materials and methods
Animals
Female C57BL/6 mice, 8-12 weeks of age, were obtained
from Japan SLC (Hamamatsu, Japan). The mice were
maintained in the specific pathogen-free animal facility at
the Institute for Animal Experiments, Hokkaido University
School of Medicine.
Tumour
BMT-1 1 tumour is a transplantable fibrosarcoma induced by
3-methylcholanthrene in a C57BL/6 mouse (Ishikawa et al.,
1987; Okada et al., 1990). The tumour cells were maintained
as a monolayer culture in Eagle's minimum essential medium
(EMEM) with 10% heat-inactivated fetal bovine serum
(FBS).
Cytokines and antibodies
Purified recombinant human (rh) IL-2 was the generous gift
of Shionogi Pharmaceutical (Osaka, Japan), and has specific
activity greater than 106 U mg-1 protein. Purified recombi-
nant human (rh) TGF-,B1 was obtained from Chemicon
International, CA, USA. The antibody against human TGF-
,B1 was a polyclonal chicken antibody with a high titre for
neutralisation of the biological activity of human or rodent
TGF-,B1 (King Brewing, Hyogo, Japan) (Tada et al., 1991).
The control anti-human IgG(Fc) IgY was obtained from
Taiyo Kagaku (Yokkaichi, Japan).
Correspondence: Y Kuramitsu, Laboratory of Pathology, Cancer
Institute, Hokkaido University School of Medicine, Kita-15, Nishi-7,
Kitahku Sapporo, 060, Japan
Received 7 November 1995; revised 13 February 1996; accepted 15
February 1996TGF-fil as a LAK attractant
Y Kuramitsu et al
Preparation of tymphokine-activated killer cells
Spleens were removed from normal C57BL/6 mice. A cell
suspension was prepared by disrupting the spleens in a loose-
fitting glass homogeniser with RPMI-1640 containing 10%
heat-inactivated FBS (10% FBS-RPMI). After the red
blood cells had been lysed by Tris-buffered ammonium
chloride, the cell suspension was washed three times in cold
10% FBS-RPMI. The spleen cells (106 ml-') were cultured
with IL-2 (1000 U ml-') in 100 mm tissue culture dishes
(Corning 25020) in 20 ml of 10% FBS-RPMI at 37°C in a
carbon dioxide incubator. After 5 days of culture, viable cells
were harvested and their cytotoxicity was determined by a
4 h 5'Cr release assay of NK cell-resistant cultured BMT-11
tumour cells.
Preparation of conditioned medium of tumour tissue
Mice were inoculated subcutaneously with BMT- 11 cells
(1 x 106) on day 0. Cyclophosphamide (CPM) (Shionogi
Pharmaceutical, Osaka, Japan), 150 mg kg-' i.v.; bleomycin
(Nippon Kayaku, Tokyo, Japan), 40 mg kg-' i.p.; doxor-
ubicin (Kyouwa Hakko, Tokyo, Japan), 10 mg kg-' i.v.;
mitomycin C (Kyouwa Hakko), 2 mg kg-' i.v.; cisplatinum
(Nippon Kayaku), 5 mg kg-' i.p.; or pepleomycin (Nippon
Kayaku), 20 mg kg-' i.p. was administered as chemotherapy
on day 10 when the tumour had grown to an average
diameter of 5 mm. Four days after the chemotherapy mice
were sacrificed. To obtain conditioned medium (CM), minced
tumour tissues were incubated in serum-free medium (ASF
103, Ajinomoto, Tokyo, Japan). After 24 h of culture at 37°C
in a 5% carbon dioxide humid air incubator, the supematant
was harvested. After centrifugation at 20 000 g for 60 min,
the supernatant was passed through 0.45 gm pore filters and
was used as CM of tumour tissue.
Under agarose migration (UAM) assay
The UAM assay is a simple method for measuring
chemotaxis and spontaneous migration of leucocytes
(Nelson et al., 1975; Chenoweth et al., 1979). Agarose
(electrophoresis purity reagent, Bio-Rad, CA, USA) was
dissolved in distilled water at a concentration of 2% by
heating in a boiling water bath for 15 min. After cooling to
48°C in a water bath, the agarose was mixed with an equal
volume of prewarmed 2 x ASF103. An aliquot of 15 ml of
the agarose medium was delivered to a gelatin-coated
culture dish and allowed to harden. Six series of three
wells 2.5 mm in diameter and spaced 3 mm apart were cut
in each plate using a stainless steel punch. The centre well
of each three-well series received 10 M1 of the cell suspension
containing 2 x 105 LAK cells. The outer wells received 10 p1
of each sample or human recombinant TGF-ll and the
inner wells received 10 p1 of ASF103 as non-chemotactic
control medium. The dishes were incubated at 37°C in a
5% carbon dioxide humid air incubator. After 3 h
incubation quantification of migration was done by
measurement of the linear distance the cells had moved
from the margin of the well towards the sample (distance
A) and the linear distance the cells had moved from the
margin of the well toward the control medium (distance B:
random migration) under the microscope. A-B was
represented as LAK-attractant activity of the sample. For
the neutralisation of LAK-attractant activity of the sample
with anti-human TGF-fil antibody, each concentration of
anti-human TGF-,ll antibody was added into the outer well
with the sample.
Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNAs were extracted from the tumour tissues
untreated or treated with anti-cancer drugs. Each RNA
sample (5 pg underwent cDNA synthesis in 50 pl of reaction
mixture containing 75 mM potassium chloride, 50 mM Tris-
HCI (pH 8.3), 3 mm magnesium chloride, 10 mM dithiother-
eitol, 0.5 mM each dNTP, 2 ig ml-' random primer, and
1000 U MMLV reverse transcriptase (Gibco, MD, USA) by
incubation at 37°C for 1 h. PCR amplification of cDNA
(5 ,lt) was performed in 50 1l containing 50 mM potassium
chloride, 10 mM Tris-HCl (pH 9.0), 2.5 mm magnesium
chloride, 0.1% Triton X-100, 200 /M each dNTP, 10 mM
each specific primer and 1 U Taq polymerase (Gibco BRL,
MD, USA). The primer pairs used were IL-la (Lomedico et
al., 1984), IL-6 (Chiu et al., 1988), IL-8 (Ohmori et al., 1990),
TNF-oa (Pennica et al., 1985), IFN-y (Gray et al., 1983),
TGF-P1 (Rugo et al., 1992) and ,B-actin (Tokunaga et al.,
1986). Table I shows the primer sequences. The primer
sequences were chosen from separate DNA exons ofthe gene.
Expected sizes of amplified DNA fragments were 341, 149,
225, 468, 408, 360 and 478 bp for IL-la, IL-6, IL-8, TNF-a,
IFN-y, TGF-,B1, and f-actin respectively. The reactions were
run for 25 and 35 cycles using a thermal cycler as follows:
1 min at 94°C, 1 min at 60°C and 2 min at 72°C. Aliquots of
9 pl of each PCR sample were mixed with 1 Ml of gel roading
buffer, electrophoresed through 1% agarose gel and stained
with ethidium bromide.
Bioassay of TGF-f3 activity
In vitro bioassay to detect TGF-,B activity was based on the
method described by Lucas et al. (1991) with some
modification. Briefly, MvlLu cells (1 x 104 per well) were
cultured with samples in 0.2 ml of RPMI-1640 medium 10%
FBS in 96-well microplates. To confirm the presence of
TGF-# in the samples, anti-human TGF-#1, 2, 3 antibodies
(100 ng ml-') were added into the detected samples. After
incubation at 37°C, 5% carbon dioxide for 72 h, 10 Mul per
well of the MTT solution [dissolved in phosphate-buffered
saline (PBS) at a concentration of 5 mg ml-'] was added for
a further 6 h incubation. Insoluble formazan crystals,
converted from the soluble MTT by surviving cells, were
dissolved by dimethyl sulphoxide (DMSO) (Mosmann,
1983). The absorbency of the formazan was measured on
a microplate reader (Corona Electric) at a test wave length
of 540 nm with a reference wavelength of 600 nm. The
amount of TGF-# present in the samples that had inhibited
50% survival of MvlLu cells was taken to be equivalent to
the amount of recombinant human TGF-# in the standard
curve.
LAK cytotoxicity assay
Target BMT-1 1 cells (1 x 106) were labelled with 100 pCi of
sodium 5'Cr (New England Nuclear, Boston, MA, USA) for
1 h and then washed three times with PBS. Approximately
1 x 105 5'Cr-labelled BMT-11 cells were plated in each well
with LAK cells. The final volume was adjusted to 200 ,ul per
well with 10% FBS-RPMI. The recombinant human TGF-
,B1 of a concentration from 0.01 ng ml-' to 10 ng ml-' was
added to the wells. The same number of target BMT-11 cells
in the same volume of 1 N hydrochloric acid and 10% FBS-
RPMI were simultaneously incubated to measure maximum
and spontaneous release respectively. After 4 h incubation at
37°C in 5% carbon dioxide, the plate was centrifuged at
1400 g for 5 min at room temperature and 100 pl of
supernatant from each well was measured with a gamma
counter machine (Aloka, Tokyo, Japan). The percentage
cytotoxicity was calculated as follows.
Cytotoxicity (%) =
experimental release -spontaneous release 100
maximum release - spontaneous release
Statistical analysis
Significant difference between two values was determined by
using the Student's t-test.TGF-fl as a LAK atbactant
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Results
The LAK-attractant activity in conditioned medium of tumour
tissues treated with various anti-cancer drugs
The chemotactic activity for LAK cells (LAK-attractant
activity) of CMs prepared from tumour tissues growing in
mice treated with various anti-cancer drugs was examined by
the UAM assay. As shown in Table II, the LAK-attractant
activity was detected in the CM of the tumour tissues from
the mice treated with cyclophosphamide (CPM), doxorubicin,
cisplatinum (CDDP), mitomycin (MMC) and pepleomycin
(PEP) respectively, whereas no LAK-attractant activity was
detected in the CMs of untreated mice or mice treated with
bleomycin (BLM). Although the random migration of LAK
cells, represented as distance B, varied in each experiment,
distance A, which is the migrating distance of LAK cells
toward CM, was greater (more than 0.3 mm) than distance B
in the above positive cases. CPM and CDDP especially
showed a significant difference between the distances A and
B.
mRNA expression of various cytokines in tumour tissues that
were untreated or treated with cyclophosphamide
In order to pursue the possibility that any cytokine was
produced in tumour tissues after chemotherapy, we examined
mRNA expression of cytokines in CPM-treated or untreated
tumour tissues. mRNA expression of IL-la, IL-6, IL-8, IFN-
y, and TNF-a was observed in untreated tumour tissues but
Table I Primer pairs for RT-PCR
Cytokine Sequence
IL-la -5' Primer 5'-ATACCGAGTGAAGTACTCTG-3'
-3' Primer 5'-TAGTCCTACACCTGTTTGTG-3'
IL-6 -5' Primer 5'-CCAGGAGAAGATTCCAAAGATGTA-3'
-3' Primer 5'-AATGAGATGAGTTGTCATGTCCTG-3'
IL-8 -5' Primer 5'-CAGTAAAAGACGGAGTAGGA-3'
-3' Primer 5'-ACTTAGGCCTTAGATTCTGG-3'
TNF-a -5' Primer 5'-AGTGACAAGCCTGTAGCCCATGTT-3'
-3' Primer 5'-AGACTCGGCAAAGTCGAGATAGTC-3'
IFN-y -5' Primer 5'-TGTTACTGCCAGGACCCATATGTA-3'
-3' Primer 5'-TCTTCGACCTTGAAACAGCATCTG-3'
TGF-,B1 -5' Primer 5'-GCTCACTGCTCTTGTGACAGCAAAG-3'
-3' Primer 5'-CAAGGACCTTGCTGTACTGTGTGTC-3'
fl-actin -5' Primer 5'-TTCGAGCAAGAGATGGCCACGGCT-3'
-3' Primer 5'-ATACTCCTGCTTGCTGATCCACAT-3'
not enhanced by the CPM treatment (Figure 1). Figure 2
shows TGF-,B1 mRNA expression in tumour tissues 24 h
after treatment with CPM by RT-PCR. Expected sizes of
360 bp (TGF-,B1) and 478 bp (fl-actin) were amplified. No
band of TGF-f31 was observed in untreated tumour tissue
mRNA after both 25 cycles and 35 cycles. On the other hand,
with CPM-treated tumour tissue mRNA, a clear band of
TGF-,Il was observed after 35 cycles. These findings suggest
that TGF-Il might be a LAK attractant produced in the
tumour tissue after chemotherapy.
The production of TGF-1 in the CMs of BMT-JJ tumour
tissues treated with anti-cancer drugs
Table III shows the activities of TGF-# in the CMs of
tumour tissues after chemotherapy. The tumour tissues
treated with CPM, CDDP and PEP produced 17.7 ng ml-',
25.3 ng ml-' and 40.3 ng ml-1 of TGF-f respectively,
whereas we could detect no TGF-# activity in the CMs of
untreated tumour tissues.
IL-6
P-Actin
Lane 1 2
Figure 1 Expression ofmRNA for IL-la, IL-6, IL-8, TNF-a and
IFN-y in murine BMT-11 tumour tissues after treatment with
cyclophosphamide (CPM). The figure shows bands stained with
ethidium bromide. Total RNAs extracted from tumour tissues
untreated or treated with CPM were analysed by RT-PCR.
Expected sizes of DNA fragments for IL-la, IL-6, IL-8, TNF-a,
IFN-y and ,B-actin were amplified. Lane 1, untreated; lane 2,
treated with CPM.
Table II LAK-attractant activities of conditioned medium of BMT-
11 tumour tissues in mice treated with various anti-
cancer drugs
Conditioned mediuma LAK-attractant activity
oftumour tissues Distance Ab Distance Bc (Mean±s.d. of (A-B)
treated with (Mean ±s.d. in mm) (Mean ±s.d. in mm) pd in mm)
None (n =7) 1.52±0.15 1.44±0.17 0.369 0.08+0.06
Cyclophosphamide (n=6) 1.61 ±0.11 1.25+0.08 <0.001 0.36± 0.06e
Doxorubicin (n =3) 1.67±0.18 1.35 ±0.09 0.051 0.32±0.22
Bleomycin (n =2) 1.50±0.18 1.46±0.05 0.791 0.04±0.04
Cisplatinum (n =3) 1.63 ±0.16 1.21+0.14 0.027 0.43±0.05e
Mitomycin (n =2) 1.81 ±0.09 1.45+0.28 0.226 0.37+0.14
Pepleomycin (n =3) 1.82+0.16 1.42+0.10 0.021 0.40+0.22
aApproximately 1 x 106 BMT-1 1 cells wereimplanted subcutaneously onday 0. Anti-cancerdrugs wereadministered onday
10 when tumours had grown to an average diameter of5 mm. Fourdays after chemotherapy mice were sacrificed andminced
tumour tissues were incubated in serum-free medium for 24 h. The supernatant was harvested from the culture dishes,
centrifuged at 20000 xg for 60 min and passed through 0.45-pm-pore size filters. bDistance A represents the linear distance
that LAK cells moved from the margin ofthe well towards the sample. cDistance B represents the linear distance that LAK
cells moved from the margin ofthe well towards the control medium. dStatistically significant difference between distances A
and B. ep<0.001 vs conditioned medium ofBMT-1 1 tumour tissues from untreated mice.TGF-,B1 as a LAK attractant
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Figure 2 Expression of mRNA for TGF-/3' in murine BMT-I I tumour tissues after treatment with cyclophosphamide (CPM). The
figure shows bands stained with ethidium bromide. Total RNA extracted from tumour tissues untreated or treated with CPM were
analysed by RT-PCR. Expected sizes of DNA fragments for TGF-j31 and /-actin were amplified. Lanes A and C, untreated; lanes B
and D, treated with CPM.
Table III The production of TGF-/3 in conditioned medium (CM)
of tumour tissues after chemotherapy
CM' of tumour tissues TGF-f1 production (ngnF'1)h
treated wiithi (Mean ±s.d.)
None Not detectable
Cyclophosphamide (CPM) 17.7 ±0.8
Cisplatinum (CDDP) 25.3 ± 4.1
Pepleomycin (PEP) 40.3 ± 4.1
aApproximately 1 x 106 BMT-11 cells were implanted subcuta-
neously on day 0. Anti-cancer drugs were administered on daylO
when tumours had grown to an average of 5 mm. Four days after
chemotherapy mice were sacrificed and minced tumour tissues were
incubated in serum-free medium for 24h. The supernatant was
harvested from the culture dishes, centrifuged at 20000 xg for 60 min
and passed through 0.45-,um-pore size filters. b The production of
TGF-,B in CM was examined by bioassay using MvlLu cells.
LAK-attractant activity of recombinant humnan TGF-/31
We examined whether or not TGF-/31 showed LAK-
attractant activity. The results indicate that recombinant
human TGF-,B1 showed definite LAK-attractant activity as
seen in Figure 3. The LAK-attractant activity of TGF-,Bl
increased in a dose-dependent manner up to 1 ng ml-',
which, however, decreased at higher concentrations than
10 ng ml-'.
The effects oJfanti-TGF-/31 antibody on LAK-attractant
activity in CM prepared from tumour tissues treated wtith
(>lclophosphamide
As we detected TGF-,lB activity in CPM-treated tumour
tissue CM, we next examined whether or not TGF-/1 in CM
prepared from tumour tissues treated with CPM participates
in LAK-attractant activity. The effects of anti-TGF-/3l
antibody have been tested on LAK-attractant activity of
the CM. Anti-TGF-/31 antibody abrogated LAK-attractant
activity in the CM of tumour tissues treated with CPM to
800/ of control at a concentration of 1 ,ug ml-', and to 35%
of control with 100 pg ml-' (Figure 4). The same concentra-
tion of control IgY could not suppress the LAK-attractant
activity of CMs.
The ef.fcts of TGF-/31 on LAK cell ci'totoxicity
From the findings mentioned above, it is revealed that TGF-
/31 produced in tumour tissues after chemotherapy could be a
LAK-attractant. However, TGF-f is known to suppress the
host immune system. There were many reports that TGF-f31
inhibited LAK activity in an induction phase, but we did not
know whether TGF-/31 inhibited LAK cell cytotoxic activity
in an effector phase or not. We measured LAK activity by a
4 h 5'Cr release assay against NK-resistant BMT-11 tumour
cells in the presence of TGF-/Jl at a concentration from
0.01 ng ml-' to 10 ng ml-' in an effector phase. At all
concentrations of TGF-/3l, no effect on LAK cell cytotoxic
activity was observed (Figure 5).
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Figure 3 LAK-attractant activities of recombinant human TGF-
/31. LAK-attractant activities were measured by UAM assay. The
incubation period for LAK cells was 3 h. The incubation period
for fresh splenocytes was 24h. Distance A represents the linear
distance the cells moved from the margin of the well towards the
sample. Distance B represents the linear distance the cells moved
from the margin of the well towards the control medium.
Directed migration represents A-B. Averages of distance B of
LAK cells and fresh splenocytes were 0.55+0.42 and 0.48+0.12
respectively (mm, mean + s.d.). _, LAK cells; C, fresh
splenocytes.
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Figure 4 The effects of anti-TGF-/31 antibody on LAK-
attractant activity of cyclophosphamide (CPM)-treated condi-
tioned medium (CM). LAK-attractant activity was measured by
UAM assay. The incubation period was 3h. A is the distance
LAK cells had moved from the margin of the well towards CM
(directed migration). B is the distance LAK cells had moved from
the margin of the well towards control medium (random
migration). The distances were measured under the microscope.
_, CM alone; = CM + anti-TGF-,lI ( ugml-1); 0,
CM + anti-TGF-/ll (100 igml 1); M, CM + chicken IgY
(lOO,ugml ).
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Figure 5 The effects ofTGF-#l on LAK activities. LAK activity
was measured by a 4h ';Cr release assay against natural killer
cell-resistant cultured BMT- II tumour cells with TGF-fl at a
concentration from 0.01 ngmlP to lOngmni.
Discussion
Results of the present study indicate that TGF-#l is one of
the LAK attractants produced in the tumour tissues after
chemotherapy and it augments effects of LAK adoptive
immunotherapy synergistically. In this report we have
analysed the mechanism of enhancement of transferred
LAK cell accumulation into tumour tissues by chemother-
apy. As adoptive transfer was carried out four days after
administration of anti-cancer drugs. the drugs were not able
to affect the LAK cells directly. In as much as chemotactic
factors are thought to be an important factor for leucocyte
migration including LAK cells. we examined whether CM of
tumour tissues from mice treated with various anti-cancer
drugs had chemotactic activity for LAK cells or not by the
UAM assay. The tumour tissue CMs from mice treated with
anti-cancer drugs represented LAK-attractant activity. As
various cytokines have been reported to have chemotactic
activity for leucocytes (Natuk et al.. 1987; Miossec et al..
1988). we have studied whether CPM induced mRNA
expression of IL-h1.. IL-2. IL-6. IL-8. IFN;. TNF-2 and
TGF-f1 in tumour tissues. Although mRNA expression of
IL-1-l. IL-2. IL-6. IL-8. IFN, and TNF-a was not enhanced
by chemotherapy. that of TGF-#l was increased in tumour
tissues after chemotherapy. We then examined the LAK-
attractant activity of recombinant human TGF-fll. TGF-fll
represented the chemotactic activity for LAK cells at a
concentration of 1 ng ml-' particularly. This reaction was
not in a dose-dependent manner. which is consistent with the
result reported by Adams et al. (1991) on monocytes and T
lymphocytes. A neutralising test using anti-TGF-PI antibody
against LAK-attractant activity in the CM of tumour tissues
from mice treated with CPM showed the possibility that
TGF-ll might be one of the LAK-attractants. TGF-Il has
been reported to have chemotactic activity for monocytes. T
lymphocytes and LAK cells (Wahl et al., 1989; Adams et al..
1991: Delens et al.. 1994). These findings suggest that TGF-
#I is one of the LAK-attractants. We are not yet able to
clarify the mechanism of production for TGF-#fI in tumour
tissue after chemotherapy. TGF-#l is one of the inflamma-
tory cytokines. Therefore it is speculated that inflammatory
cytokines such as IL-1. IL-6 and TNF-x will be produced in
tumour tissues by chemotherapy. and that they will induce
the production of TGF-fl from host reactive cells in
combination with cytotoxic effects of anti-cancer drugs.
Although we cannot yet identify the TGF-fll-producing
cells. our preliminary data suggested that LAK attractant
was produced by host reactive cells.
TGF-Il is well known as an immunosuppressor (Tada et
al., 1991). IfTGF-#1 is one of the LAK attractants produced
in tumour tissues after chemotherapy. inhibition of LAK
activity will cause a discrepancy in synergistic therapeutic
effects of the combination therapy. From a 4 h "Cr release
assay against NK cell-resistant BMT-11 tumour cells. we can
refute the possibility that TGF-PI inhibits LAK activity in an
effector phase. Although TGF-fI does not suppress LAK
activity, it is possible that TGF-#l suppress the secondary
immunoreaction to tumour cells after LAK therapy. In an
animal model for IL-2-immunotherapy in combination with
CPM. we could not observe any tumour-specific resistance in
cured mice (Hosokawa et al., 1988). The fact that TGF-fl is
produced in tumour tissues after chemotherapy may be one
of reasons why it has not proved possible to induce the
tumour-specific T-cell reaction in surviving mice.
Our findings that the combination therapy of LAK
adoptive immunotherapy and cancer chemotherapy increases
therapeutic effects synergistically and LAK cells accumula-
tion into tumour tissues can be explained by chemotactic
function ofTGF-fI as a LAK attractant produced in tumour
tissues after chemotherapy. although the enhanced accumula-
tion of transferred LAK cells cannot be explained by
chemotactic function of TGF-#l only. Wahl et al. (1993)
have shown that TGF-fi1 enhanced integrin expression and
type IV collagenase secretion in human monocytes. It is
possible that TGF-#I also enhanced integrin expression and
type IV collagenase secretion in LAK cells.
Many investigators studying LAK cell motility showed
that most of the LAK cells transferred i.v. first accumulate in
the lungs 1 h after transfer, and in the liver and spleen 24 h
after transfer. but only a few accumulate in tumour tissues
(Lotze et al.. 1980; Hosokawa et al., 1988: Maghazachi et al.,
1988: Ames et al.. 1989: Felgar et al.. 1990; Futami et al..
1991). Therefore. effectiveness of LAK adoptive immunother-
apy is thought to depend greatly on the accumulation in
tumour tissues. We have previously reported that chemother-
apy for tumour-bearing mice enhanced the accumulation of
LAK cells in tumour tissues (Hosokawara et al.. 1988:
Kawata et al.. 1990: Hosokawa et al.. 1992). Pockaj et al.
(1994) have also reported that CPM administration before
tumour infiltrating lymphocyte (TIL) and IL-2 therapy and
the administration of large numbers of TILs improved the
frequency of TIL localisation to tumour in human clinical
study. This report is able to clarify the mechanism by which
these chemotherapies enhance the accumulation of LAK cells
in tumour tissues.
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